doi: 10.1016/0304-3940(89)90826-4
manufactured in a GMP-certified facility, rigorously tested for purity and potency.
About 80% of the patients were taking it for diabetes reasons, and among the total cohort, that average weight loss at 1 year was 5%
If the efficacy readouts from SURMOUNT-1 are reproducible, Lilly almost certainly has a best-in-class medication this may be plainly reflected in the SURMOUNT-5 Phase 3b trial readout (1H 2025)
However, specialized sports anti-doping tests (like those administered by WADA or USADA) do test for GLP-1 receptor agonists and related compounds
Deferiprone, as the first available oral iron chelator approved in Europe since 1999, had not been approved by the FDA until 2011 due to concerns about serious effects (Mobarra et al., 2016